Althea Partners

Total investments

1

Average round size

6M

Portfolio companies

1

Lead investments

1

Stages of investment
Early Stage Venture
Areas of investment
BiotechnologyHealth CareMedicalPharmaceutical

Summary

The typical case for the fund is to invest in rounds with 1 participant.

Among the various public portfolio startups of the fund, we may underline Cornerstone Pharmaceuticals Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical, Pharmaceutical.

The top activity for fund was in 2010. The usual things for fund are deals in the range of 5 - 10 millions dollars. The fund is constantly included in less than 2 investment rounds annually.

Show more

Investments analytics

Analytics

Total investments
1
Lead investments
1
Investments by industry
  • Pharmaceutical (1)
  • Biotechnology (1)
  • Health Care (1)
  • Medical (1)
Investments by region
  • United States (1)
Peak activity year
2010

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
21

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Rafael Pharmaceuticals 26 Jan 2010 Biotechnology, Health Care, Medical, Pharmaceutical Early Stage Venture 6M United States, New Jersey
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.